Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
36171104
DOI
10.1136/jnnp-2022-329987
PII: jnnp-2022-329987
Knihovny.cz E-zdroje
- Klíčová slova
- MULTIPLE SCLEROSIS, STATISTICS,
- MeSH
- analýza latentních tříd MeSH
- chronicko-progresivní roztroušená skleróza * farmakoterapie MeSH
- lidé MeSH
- postižení * MeSH
- progrese nemoci MeSH
- registrace MeSH
- roztroušená skleróza * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Over the decades, several natural history studies on patients with primary (PPMS) or secondary progressive multiple sclerosis (SPMS) were reported from international registries. In PPMS, a consistent heterogeneity on long-term disability trajectories was demonstrated. The aim of this study was to identify subgroups of patients with SPMS with similar longitudinal trajectories of disability over time. METHODS: All patients with MS collected within Big MS registries who received an SPMS diagnosis from physicians (cohort 1) or satisfied the Lorscheider criteria (cohort 2) were considered. Longitudinal Expanded Disability Status Scale (EDSS) scores were modelled by a latent class growth analysis (LCGA), using a non-linear function of time from the first EDSS visit in the range 3-4. RESULTS: A total of 3613 patients with SPMS were included in the cohort 1. LCGA detected three different subgroups of patients with a mild (n=1297; 35.9%), a moderate (n=1936; 53.6%) and a severe (n=380; 10.5%) disability trajectory. Median time to EDSS 6 was 12.1, 5.0 and 1.7 years, for the three groups, respectively; the probability to reach EDSS 6 at 8 years was 14.4%, 78.4% and 98.3%, respectively. Similar results were found among 7613 patients satisfying the Lorscheider criteria. CONCLUSIONS: Contrary to previous interpretations, patients with SPMS progress at greatly different rates. Our identification of distinct trajectories can guide better patient selection in future phase 3 SPMS clinical trials. Additionally, distinct trajectories could reflect heterogeneous pathological mechanisms of progression.
Amiri Hospital Kuwait City Kuwait
Biogen International Zurich Switzerland
CHUM and Universite de Montreal Montreal Quebec Canada
Clinical Neuroscience Karolinska Institute Stockholm Sweden
CORe Department of Medicine University of Melbourne Melbourne Victoria Australia
Department of Clinical Epidemiology Aarhus University Hospital Aarhus Denmark
Department of Health Sciences University of Genoa Genoa Italy
Department of Neurology Box Hill Hospital Melbourne Victoria Australia
Department of Neurology Danish Multiple Sclerosis Center Rigshospitalet Copenhagen Denmark
Department of Neurology Razi Hospital Manouba Tunisia
Department of Neurology Razi University Hospital Manouba Tunisia
Department of Neurology Royal Melbourne Hospital Melbourne Victoria Australia
Department of Neurology Zuyderland Medical Center Sittard Geleen The Netherlands
Department of Neuroscience Monash University Central Clinical School Melbourne Victoria Australia
Dokuz Eylul University İzmir Turkey
Faculty of Health Sciences University Fernando Pessoa Porto Portugal
Faculty of Medicine of Tunis University of Tunis El Manar Tunis Tunisia
Groene Hart Ziekenhuis Gouda The Netherlands
Managing Director MSBase Foundation Melbourne Victoria Australia
Monash University Central Clinical School Melbourne Victoria Australia
Neuro Rive Sud Quebec Quebec Canada
Neurology Box Hill Hospital Melbourne Victoria Australia
Neurology Centro Hospitalar de São João Porto Portugal
Neurology Cliniques Universitaires Saint Luc Brussels Belgium
Neurology Donostia University Hospital San Sebastian Spain
Neurology Galdakao Hospital Vizcaya Spain
Neurology Hospital Universitario Virgen Macarena Sevilla Spain
Neuroscience Centre Clinical School Monash University Victoria Australia
Ondokuz Mayis Üniversitesi Samsun Turkey
School for Mental Health and Neuroscience Maastricht University Maastricht The Netherlands
Service de Neurologie A Hopital Neurologique Hospices Civils de Lyon Lyon Bron France
UQCCR The University of Queensland Brisbane Queensland Australia
Citace poskytuje Crossref.org
Big Multiple Sclerosis Data network: an international registry research network